Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. - Wikidata - awgldk - TriplyDB

Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.

Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.

http://www.wikidata.org/entity/Q37369828

about

The challenge of developmental therapeutics for adrenocortical carcinoma Human adrenocortical carcinoma cell lines.Therapy of adrenocortical cancer: present and future.Current and emerging therapies for advanced adrenocortical carcinoma.Bone Targeted Therapies for Bone Metastasis in Breast Cancer Current management options for recurrent adrenocortical carcinoma.Outcomes after resection of cortisol-secreting adrenocortical carcinoma Novel targeted therapies in adrenocortical carcinoma.Adrenocortical carcinoma: past, present, and future.Management of adjuvant mitotane therapy following resection of adrenal cancer.The use of mass spectrometry to improve the diagnosis and the management of the HPA axis.Recent developments in drug therapy for Cushing's disease.Management of adrenal cancer: a 2013 update.Aldosterone-secreting adrenal cortical carcinoma. A case report and review of the literature.Cushing's syndrome: an update on current pharmacotherapy and future directions.Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE).Proteome analysis of adrenal cortical tumors.Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro.Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells.Potent antitumor activity of HSP90 inhibitor AUY922 in adrenocortical carcinoma.Repeated resections for liver metastasis from primary adrenocortical carcinoma: A case report.Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma.Resection of adrenocortical carcinoma liver metastasis: is it justified?Significance of heparanase-1 and vascular endothelial growth factor in adrenocortical carcinoma angiogenesis: potential for therapy.CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells.Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis.

P2860

Q28072970-1D036F0E-A7D4-4823-BA89-32B31C133940 Q34216956-C0038014-5066-417F-8A87-45738768BE94 Q35232257-C8B58CBE-C7A4-4A22-BA7F-081EC9CA10F1 Q35584305-AE48FA34-0634-4E5C-9A21-B66BE1EE7ED7 Q35750448-7C0F940F-B5EC-49D0-B48F-68234B005265 Q36925876-4EA2D183-329E-44B3-A3DD-2A51F12EEC1D Q37119591-63F1792C-9B44-4CB8-9AAF-79C7C86E3ED0 Q37233378-4B569312-B3C5-4A5B-9A31-6F36029F48FA Q37999696-8022D2CF-9AA2-4453-AA2E-E40C8A71C49E Q38019388-0E9E211D-3716-4312-889A-57FF981AF200 Q38089640-F9A2956F-2E1D-4C66-8219-D1F32E5F96D3 Q38112082-79F28413-3C9F-4AF8-85E2-34B90DCEF7AB Q38181425-217C80AD-4684-4394-A2BD-F8B7DF3556D8 Q38200547-8DA3DE94-3510-46DF-A05B-0E835DACE4DC Q38541695-C6BDC9D8-8E88-47A9-9A25-8C64A09140A2 Q38545507-B640F4F1-4893-47D8-AA1D-906E27A91CCF Q38888303-F4FB22AE-EF95-4D75-8329-0EABEA4DE744 Q38925278-EFF74840-B4B8-4BDB-A7D6-385EFB8B9E4A Q38968381-5C6FABA7-51A4-4E4B-AF7E-EC44B34F2668 Q38992870-77825C4D-3BB0-4789-93D5-D3AC133AD886 Q39479211-01DF0B77-EB00-4144-98D7-12B159FAA3E8 Q50091898-87F66352-8B77-46CF-943F-9EBF8E7469CD Q54313412-C29733E0-514B-4371-98ED-18CE4E6249EE Q54578853-40F85520-E527-4EFE-ABDD-DE06493E7DD5 Q55091442-984048F0-FEEE-49B6-8E9B-689E10C5AE32 Q55399185-B73AAC59-F54A-49B8-9077-B384B048F1A8

P2860

Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.

http://www.wikidata.org/entity/Q37369828

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 August 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Management of endocrine manife ...... for adrenocortical carcinoma.

@en

Management of endocrine manife ...... for adrenocortical carcinoma.

@nl

type

label

Management of endocrine manife ...... for adrenocortical carcinoma.

@en

Management of endocrine manife ...... for adrenocortical carcinoma.

@nl

prefLabel

Management of endocrine manife ...... for adrenocortical carcinoma.

@en

Management of endocrine manife ...... for adrenocortical carcinoma.

@nl

P1433

Q37369828-54BC2A2D-1A2B-4812-964B-CA66629EFF4D

P1476

Q37369828-83B2E787-A20A-4877-9BBC-84137C26545B

P2093

Q37369828-82541BF6-7582-46A6-8E96-173F4D623EE3

Q37369828-8F3E2F7F-B3CD-44BD-ABB3-DC7E5A256C41

Q37369828-AAB794C1-E45A-4029-A981-05830B2EFF8B

P2860

Q37369828-0532258A-2725-4C21-95A6-CAB8A3A385ED

Q37369828-0C2B84CD-7780-4469-AC20-5B9D1D53BCD5

Q37369828-101F8310-AED0-4056-86B4-35089D44B6CA

Q37369828-105127EC-8CA9-41F2-A2AD-DFED788D3A46

Q37369828-11AC833B-6D97-487E-AE4D-3F2F1E0716E9

Q37369828-140564EC-49E6-487E-95CE-414A5D98E1C4

Q37369828-1CFAC746-65BC-43D4-AE85-DB7CA615C714

Q37369828-1E4DAB13-F03F-4331-836F-DDCC87CA29CE

Q37369828-2A577000-4F19-48A0-A63F-BD1BDDDA07A6

Q37369828-2B8365C2-A825-4017-8934-1341D44C93B8

P304

Q37369828-67D9D303-4AEC-4529-AEA4-A0135E7B2C0F

P31

Q37369828-B9F54BD8-C0CF-4612-BA77-83B237EAFF2A

P356

Q37369828-9A8302E7-8ED2-405C-A1A8-8CB6559A3172

P407

Q37369828-C7E6534F-845E-4BCC-A848-F746904BBDE3

P433

Q37369828-E46B4888-0D0A-4986-B2E7-68EB22E1214B

P478

Q37369828-EE2A4253-A76C-4339-AA0B-E760B6363E51

P577

Q37369828-0BD98531-D443-4225-AC33-8A8A1AA4E1EA

P698

Q37369828-27EFDD55-2FF3-4157-8CBE-30F6AD82A4DA

P921

Q37369828-573598FC-53F4-4F5A-99A3-4ABEC395A92A

P932

Q37369828-A274D6FF-774E-4386-A96B-34EBA50A6625

P356

JCO.2008.17.2775

P1433

Journal of Clinical Oncology

P1476

Management of endocrine manife ...... for adrenocortical carcinoma.

@en

P2093

Irina Veytsman

http://www.w3.org/2001/XMLSchema#string

Lynnette Nieman

http://www.w3.org/2001/XMLSchema#string

Tito Fojo

http://www.w3.org/2001/XMLSchema#string

P2860

Mitotane for adrenocortical carcinoma treatment

Inhibition of adrenal steroidogenesis by the anesthetic etomidate

The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states

Adjuvant mitotane treatment for adrenocortical carcinoma

Possible mechanism and treatment of o,p'DDD-induced hypercholesterolaemia

Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use.

A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.

Mitotane use in inoperable adrenal cortical carcinoma.

Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.

Ketoconazole binds to glucocorticoid receptors and exhibits glucocorticoid antagonist activity in cultured cells.

P304

4619-4629

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.17.2775

http://www.w3.org/2001/XMLSchema#string

P407

P433

27

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2009-08-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19667279

http://www.w3.org/2001/XMLSchema#string

P921

P932

2754909

http://www.w3.org/2001/XMLSchema#string